Afuco™ Anti-CD3E ADCC Therapeutic Antibody (Otelixizumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from rat) antibody to Human CD3E. Otelixizumab, also known as TRX4, is a monoclonal antibody, which is being developed for the treatment of type 1 diabetes and other autoimmune diseases.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-H52 |
| Pricing | Inquiry |
| Host | Human |
| Target | CD3E |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS, IF |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |